PBK1 Modulators for Beta Cell Regeneration in Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes, such as insulin and sulfonylureas, fail to prevent β-cell death or re-establish β-cell mass, leading to progressive deterioration in glycemic control, and existing oral antidiabetic drugs like Byetta have limitations including injection requirements and side effects.
Innovation Solution
Development of compositions and methods utilizing PBK1 protein and DNA to improve glucose sensing by pancreatic β-cells, including detecting autoantibodies for type 1 diabetes and using PBK1 modulators to treat type 2 diabetes by enhancing insulin secretion and β-cell regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments like insulin and sulfonylureas are used to lower blood glucose, then glycemic control is achieved, but β-cell death is not prevented and β-cell mass is not re-established
Solution Approach 1:
The patent introduces PBK1 as an intermediary target that mediates between glucose sensing and insulin secretion. By developing compounds that modulate PBK1 activity, the invention creates a new therapeutic pathway that protects β-cells while maintaining glycemic control, rather than directly addressing glucose levels or β-cell mass separately.
Solution Approach 2:
The patent changes the therapeutic parameter from direct glucose lowering to PBK1 kinase activity modulation. By identifying compounds that activate or inhibit PBK1, the invention shifts the control parameter to a molecular level target that influences both glucose sensing and β-cell survival, thereby addressing both glycemic control and β-cell mass preservation simultaneously.
2Reliability
If oral hypoglycemic agents are used to treat type 2 diabetes, then blood glucose is lowered, but efficacy is lost over time due to progressive deterioration in β-cell function
Solution Approach 1:
The patent applies preliminary action by protecting β-cell function before complete deterioration occurs. By targeting PBK1, which is involved in glucose sensing and insulin secretion, the compounds aim to preserve β-cell function proactively, preventing the progressive deterioration that leads to loss of drug efficacy over time.
Solution Approach 2:
The patent incorporates feedback mechanisms by targeting PBK1, a kinase involved in the glucose-sensing pathway. Modulating PBK1 activity creates a feedback loop that responds to glucose levels while protecting β-cell function, thereby maintaining drug efficacy over the long term by preventing β-cell exhaustion.
3Reliability
If Byetta (exenatide) is used to improve β-cell function, then glucose sensing is improved and β-cell mass is preserved, but the drug requires injection twice daily and causes gastrointestinal discomfort
Solution Approach 1:
The patent replaces the mechanical injection system with an oral administration system. By identifying small molecule compounds that can be orally administered and that target PBK1, the invention substitutes the injection mechanism with an oral dosage form, thereby improving ease of operation while maintaining the therapeutic benefits of β-cell function improvement.
Solution Approach 2:
The patent changes the administration parameter from parenteral (injection) to oral. By developing orally bioavailable compounds that target PBK1, the invention alters the route of administration parameter, eliminating the need for injections and reducing gastrointestinal discomfort associated with peptide-based therapies like exenatide.
4Loss of substance
If Byetta (exenatide) is used to treat type 2 diabetes, then β-cell mass is preserved, but anti-exenatide antibodies develop in diabetic subjects
Solution Approach 1:
The patent employs small molecule compounds that can be synthesized and administered orally, replacing the peptide-based exenatide. These small molecules are less likely to induce antibody formation, providing a durable long-term treatment solution that maintains β-cell mass without the immunogenicity problems of peptide therapies.
Solution Approach 2:
The patent substitutes the peptide structure of exenatide with small molecule structures that target PBK1. This structural substitution reduces immunogenicity and antibody formation while maintaining the ability to preserve β-cell mass, thereby ensuring long-term treatment efficacy.
Data Source
AI summary
The invention relates to compositions comprising, and methods utilizing PBK1 protein and DNA, including a method of detecting type 1 diabetes; a mammalian pancreas-derived cell comprising a recombinant nucleic acid encoding a PBK1 protein; a method of identifying a PBK1 modulator; a pharmaceutical composition for treatment of type 2 diabetes in a subject; a method of screening for an agent that treats a metabolic disease; delivery of PBK-1 DNA to a subject to stimulate pancreatic beta cell differentiation and/or regeneration; a method for stimulating cell differentiation and/or regeneration in a pancreatic beta cell; usage of transgenic mice with targeted deletion or overexpression of the PBK-1 gene to test efficacy and specificity of PBK-1 modulator compounds.